Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected

Marie Tré-Hardy; Roberto Cupaiolo; Alain Wilmet; Thomas Antoine-Moussiaux; Nicoleta Coman-Vlagea; Andrea Della Vecchia; Alexandra Horeanga; Emmanuelle Papleux; Marc Vekemans; Ingrid Beukinga; Laurent Blairon

doi:10.1016/j.jinf.2022.02.009

Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected

Marie Tré-Hardy, Roberto Cupaiolo, Alain Wilmet, Thomas Antoine-Moussiaux, Nicoleta Coman-Vlagea, Andrea Della Vecchia, Alexandra Horeanga, Emmanuelle Papleux, Marc Vekemans, Ingrid Beukinga, Laurent Blairon

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e31-e33
Journal	Journal of Infection
Volume	84
Issue number	4
DOIs	https://doi.org/10.1016/j.jinf.2022.02.009
Publication status	Published - Apr 2022

Funding

None declared. This study has been approved by the Ethical Committee of the HIS-IZZ (ethical agreement number: CEHIS/2021-007).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jinf.2022.02.009

Cite this

@article{c4c32fa65d6b4d15a1e16c30ddf471db,

title = "Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected",

author = "Marie Tr{\'e}-Hardy and Roberto Cupaiolo and Alain Wilmet and Thomas Antoine-Moussiaux and Nicoleta Coman-Vlagea and {Della Vecchia}, Andrea and Alexandra Horeanga and Emmanuelle Papleux and Marc Vekemans and Ingrid Beukinga and Laurent Blairon",

note = "Funding Information: None declared. This study has been approved by the Ethical Committee of the HIS-IZZ (ethical agreement number: CEHIS/2021-007).",

year = "2022",

month = apr,

doi = "10.1016/j.jinf.2022.02.009",

language = "English",

volume = "84",

pages = "e31--e33",

journal = "Journal of Infection",

issn = "0163-4453",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Assessment 2 months after the administration of a 3rd dose mRNA

T2 - a new variant-adapted vaccine is expected

AU - Tré-Hardy, Marie

AU - Cupaiolo, Roberto

AU - Wilmet, Alain

AU - Antoine-Moussiaux, Thomas

AU - Coman-Vlagea, Nicoleta

AU - Della Vecchia, Andrea

AU - Horeanga, Alexandra

AU - Papleux, Emmanuelle

AU - Vekemans, Marc

AU - Beukinga, Ingrid

AU - Blairon, Laurent

N1 - Funding Information: None declared. This study has been approved by the Ethical Committee of the HIS-IZZ (ethical agreement number: CEHIS/2021-007).

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85127756252&partnerID=8YFLogxK

U2 - 10.1016/j.jinf.2022.02.009

DO - 10.1016/j.jinf.2022.02.009

M3 - Letter

C2 - 35181372

AN - SCOPUS:85127756252

SN - 0163-4453

VL - 84

SP - e31-e33

JO - Journal of Infection

JF - Journal of Infection

IS - 4

ER -

Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected

Funding

UN SDGs

Access to Document

Other files and links

Cite this